Key Takeaways
- Margin recovery drives the quarter: API EBIT margin jumped to 21.7% and specialty chemicals turned positive at 5%, both on better utilization and softer raw material costs.
- Ibuprofen volume, not price, is the engine: Revenue hit ~₹250 Cr in Q4 as capacity utilization rose from 60-70% to 85-90%, while prices stayed flat for two straight quarters.
- Paracetamol is the next growth leg: Capacity doubled to 3,600 TPA, European CEP approval landed days before the call, and management claims it will be the world's first fully backward-integrated Paracetamol producer.
- Guidance is deliberately conservative: 10-15% revenue growth and 15-16% EBITDA margin are the official numbers, but management openly flagged a "likelihood" of outperformance.
- What to watch next quarter: Whether Paracetamol's promised double-digit incremental growth materializes, the acetic anhydride plant commercializes within this quarter, and how much of the Q4 margin improvement proves sticky.
Margin Recovery & Profitability
- API margin surge: EBIT margin reached 21.7% in Q4, driven by increased demand, better capacity utilization, and some raw material cost reduction. Management considers 15-18% sustainable for the API business.
- Specialty chemicals turned the corner: Segment EBIT margin swung to a positive 5% in Q4 after clearing high-cost inventory in Q3, helped by softening raw material prices that began easing from Q3 onward.
- Gross margin lift: Rose significantly quarter-on-quarter to 35.7%, and management expects to maintain or improve it.
- Chemical segment FY23 pain: Full-year profit collapsed from ₹59 Cr in FY22 to ₹19 Cr in FY23, blamed entirely on earlier high-cost inventory and input price volatility, both now largely behind the company.
- Sustainable margin framework: Management guided 12-15% sustainable EBITDA margin for APIs (16-17% is "on the higher side") and higher single digits for the chemical segment.
Abhay Raj Singh: "We assume and we consider that anything in the API business around 15% to 17%, 18% is very much sustainable."
Ibuprofen: Volume-Led Growth & Competitive Moat
- Utilization drove the quarter: Ibuprofen revenue reached ~₹250 Cr in Q4 as capacity utilization climbed from 60-70% to 85-90%. Prices remained stable for two consecutive quarters, so the entire growth was volume-driven.
- Demand seen as sustainable: Management expects utilization to hold at 85-90% of capacity, with no demand softness flagged.
- China capacity threat contained: No new fresh Ibuprofen capacity is coming from China, per management's knowledge, because Chinese producers require Isobutyl Benzene, for which India is the sole supplier and which they cannot produce domestically.
- BASF plant status unknown: BASF announced an Ibuprofen plant in Germany in 2019 but has made no official announcement since about operationalization, leaving the competitive landscape unchanged.
Rakesh Mahajan: "China is not coming with any new fresh capacity as per our knowledge because they require the Isobutyl Benzene, for which India is the only supplier. They are not able to produce Isobutyl Benzene there."
Paracetamol: Capacity, Approvals & Backward Integration
- Capacity doubled, approval secured: Paracetamol capacity increased from 1,800 TPA to 3,600 TPA in the March quarter, and CEP approval for the European market was received approximately two days before the call.
- Incremental growth expected immediately: Double-digit growth from Paracetamol is forecast from Q1 FY24, with regulated-market revenue expected to flow after 2-3 quarters once the European approval translates into commercial shipments.
- Backward integration claim: Management stated IOL will be the first company in the world to be fully backward-integrated for Paracetamol. PAP (Para Amino Phenol) has been developed in-house and is consumed entirely for captive Paracetamol production, with no outside purchases.
- PAP capacity and PLI: PAP capacity will increase in synchronization with overall Paracetamol capacity. The company is trying to get PAP listed under the PLI scheme but has received no approval to date. Surplus PAP would be considered for outside sale only after captive needs are met.
- Margin impact undisclosed: Management declined to quantify the incremental EBITDA per ton from backward integration, saying only that margins will be better than peers.
Rakesh Mahajan: "As of our information, we will be the first company in the world which is backward integrated."
Non-Ibuprofen APIs & Regulatory Pipeline
- High single-digit growth in Q4: Non-Ibuprofen API revenue grew YoY in high single digits, held back because the full expanded Paracetamol capacity was not available during the quarter.
- Aggressive volume target for FY24: Management is considering around 50% growth for non-Ibuprofen APIs in FY24.
- Profitability expected to improve: Non-Ibuprofen segment profitability is likely to be maintained or get better next year, supported by improving product mix and increased DMF filings.
- USFDA inspection timing uncertain: DMFs have been filed but no inspection date can be fixed. Three years have passed since October '22, and management noted USFDA is currently prioritizing units with life-threatening risk, implying a potentially extended wait.
- Metformin improvement: Profitability improved in Q4 as market prices stabilized and raw material (DCDA) costs softened. Aurobindo is setting up a DCDA plant that may come online in 2-3 years; until then, China remains the only source.
Specialty Chemicals: Recovery & Europe Entry
- Ethyl acetate cycle bottomed: Prices of both ethyl acetate and acetic acid are now stable, and the cycle appears to have bottomed in the December quarter with no further threats anticipated.
- REACH certificate unlocks Europe: Obtained six months prior, the REACH certificate now enables ethyl acetate shipments to Europe, which management expects will add to margin contribution.
- Acetic anhydride imminent: The acetic anhydride plant is expected to be commercialized within Q1 FY24.
- Export momentum: Chemical segment exports increased with better realizations after obtaining the REACH certificate, contributing to the segment's return to profitability.
Capital Allocation & Balance Sheet
- FY24 CAPEX: ₹150-200 Cr, with most directed toward growth projects, approximately ₹50 Cr for maintenance, and the remainder for backward integration, land procurement, and ETT improvement.
- Annual run-rate: Management expects ₹150-200 Cr of CAPEX on a year-on-year basis as a designed and planned level.
- Commercialization timelines diverge: API projects take more than two years from investment to commercialization, while chemical projects can start immediately after plant setup.
- Receivables normalized: Receivable days rose to ~83 days from 50-55 days in FY20-21 because new products required extended credit to stabilize. Management says this has now normalized and expects ~80 days going forward.
- SAP investment: Intangible assets under development increased to ₹8 Cr, representing investment in SAP licensing and related items.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 10-15% from FY23 base, on a conservative basis | FY24 |
| Overall EBITDA margin | Maintain around 15-16% | Ongoing |
| API segment sustainable EBITDA margin | 12-15% | Ongoing |
| Chemical segment sustainable EBITDA margin | Higher single digits | Ongoing |
| Paracetamol incremental growth | Double digits | From Q1 FY24 |
| Paracetamol regulated-market revenue | Meaningful contribution after European CEP approval | 2-3 quarters from May 2023 |
| Acetic anhydride plant commercialization | Plant operational | Q1 FY24 |
| Non-Ibuprofen API volume growth | ~50% growth targeted | FY24 |
| CAPEX | ₹150-200 Cr | FY24 |
| Receivable days | Normalized at ~80 days | Going forward |
| Gross margin | Maintain or improve from 35.7% | Ongoing |
| Quarterly performance | Maintain or improvise Q4 performance | Coming quarters |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Total income | ₹596 cr, vs ₹579 cr YoY and ₹530 cr QoQ |
| EBITDA | ₹104.5 cr, vs ₹50 cr YoY and ₹49.7 cr QoQ |
| EBITDA margin | 17.5%, vs 8.6% YoY and 9.4% QoQ |
| Net profit | ₹65.3 cr, vs ₹27.7 cr YoY and ₹24.2 cr QoQ |
| Gross margin | 35.7% |
| Pharma segment EBIT margin | 21.7%, vs 13.5% YoY and 11.5% QoQ |
| Specialty chemical segment EBIT margin | 5%, vs -2.2% YoY and -0.5% QoQ |
| Revenue growth guidance (FY24) | 10%–15% on a conservative basis |
| CAPEX target (FY24) | ₹150 cr to ₹200 cr |
| CAPEX incurred (FY23) | ₹220 cr |
| Ibuprofen capacity utilization | 85%–90%, up from 60%–70% two to three quarters ago |
| Non-Ibuprofen volume growth target (FY24) | ~50% |
| Exports to regulated markets | ~40% of total export revenue |
| Full-year exports (FY23) | ₹634 cr, vs ₹546 cr in FY22 |
| Receivable days | ~83 days, normalized level 80 days |